Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading partner for integrated, high-value-added drug discovery and development solutions, today announced that Biogen Idec (Nasdaq: BIIB) has selected Evotec OAI as one of its service providers for chemical process research and development and cGMP manufacturing. The companies have expanded their relationship under a master services agreement. The objective of the collaboration is to progress one of Biogen Idec's development candidates rapidly through preclinical testing into clinical trials through provision of Evotec OAI's integrated chemical and pharmaceutical development platform, EVOdevelop(TM).
 
Evotec OAI has built a strong reputation and track record through its collaboration with Biogen Idec, which began over 5 years ago. The companies have worked together on a variety of projects including novel route selection all the way through to scale-up and cGMP manufacturing using Evotec OAI's world-class expertise in Active Pharmaceutical Ingredient development and manufacturing.
 
Dr Mario Polywka, President Chemical and Pharmaceutical Development Division at Evotec OAI, said: "We are extremely delighted that Biogen Idec continue to work with Evotec OAI as a partner to progress their small molecule development candidate. Our long term partnership with Biogen Idec is a strong validation of our chemical development capability and we look forward to building on our successful collaboration."
 
EVOdevelop(TM)
Evotec OAI, through its integrated platform, EVOdevelop(TM), is ideally positioned to address it's partners' needs for chemical and pharmaceutical development resources and expertise in order to allow them to move development candidates time and cost effectively through pre-clinical testing into clinical trials and ultimately to market.
EVOdevelop(TM) integrates leading skills and state-of-the-art laboratory and production facilities in process research and development, custom preparation, scale-up and manufacturing and formulation - all supported by the very best in analytical and regulatory expertise.
With over 10 years of experience Evotec OAI has a proven track record in drug development and, to date, has supported more than 200 partners, in particular biotechnology companies.
 
About Evotec OAI AG
Evotec OAI has established itself as the partner of choice for drug discovery and development solutions for pharmaceutical and biotechnology companies worldwide, maintaining its leadership role through innovation and unmatched customer service.
The Company's business strategy is clearly focussed on drug discovery. It has established the most comprehensive technology platform and skills that integrate its world-class biology and chemistry capabilities. Evotec OAI leverages this discovery engine in providing assay development and screening through to compound optimisation and drug manufacturing services to a broad and well-established network of customers. In addition, the Company engages in selected discovery programmes itself to develop drug candidates for early out-licensing. Evotec OAI's instrument and technology business is now successfully handled by its affiliate, Evotec Technologies.
With over 600 people in Hamburg, Germany and Oxfordshire, UK, Evotec OAI is dedicated to returning value to its shareholders and employees through a sustainable business strategy that balances short-term and long-term revenue opportunities.
www.evotecoai.com
 
Contact: Anne Hennecke, Investor Relations, Evotec OAI AG, Phone: +49-40-56081-286, anne.hennecke@evotecoai.com
Contact: Anne Hennecke, Investor Relations, Evotec OAI AG, Phone: +49-40-56081-286, anne.hennecke@evotecoai.com